Lensar, INC 8-K filings

LENSAR, Inc. announced robust second quarter 2026 financial results, showcasing 18% total revenue growth and a significant swing to positive net income and Adjusted EBITDA.

LENSAR, Inc. has appointed Michael A. Rossi as Interim CFO and scheduled its 2026 annual meeting for August 4, 2026.

LENSAR, Inc. announced first quarter 2026 financial results, showing a slight decrease in total revenue compared to the prior year, primarily due to market disruption from a terminated merger, while recurring revenue saw a 9% increase.

LENSAR, Inc. announced that Chief Financial Officer Thomas R. Staab, II will resign from his position effective May 8, 2026.

LENSAR, Inc. announced fourth quarter and full year 2025 financial results, highlighting significant growth in ALLY system adoption and recurring revenue despite a terminated merger.

LENSAR and Alcon have mutually agreed to terminate their merger agreement due to anticipated U.S. regulatory challenges, with LENSAR retaining a $10 million deposit.

LENSAR, Inc. amended its previous filing to clarify the terms of a $9.2 million revolving credit facility secured with Wells Fargo Bank, N.A.

LENSAR, Inc. announced a new $50 million revolving credit facility with Wells Fargo Bank, secured by a designated brokerage account.

LENSAR, Inc. announced an update on its pending acquisition by Alcon, now expecting to close in the first half of 2026 due to ongoing FTC review.

LENSAR, Inc. announced the results of its annual meeting, where stockholders re-elected three Class II directors and ratified PricewaterhouseCoopers LLP as its independent auditor.

LENSAR reported a 6% revenue increase in Q3 2025 driven by procedure volume, but its acquisition by Alcon is now expected to close in Q1 2026, later than anticipated.

LENSAR, Inc. announced its 2025 annual meeting for December 18, 2025, contingent on the non-completion of its proposed merger with Alcon Research, LLC.

LENSAR, Inc. reported strong second quarter 2025 operational performance with increased revenue and procedure volumes, as its proposed merger with Alcon progresses towards an expected year-end close.

LENSAR, Inc. stockholders overwhelmingly approved the proposed merger with Alcon Research, LLC's subsidiary, VMI Option Merger Sub, Inc., at a special meeting held on July 2, 2025.

LENSAR, Inc. and Alcon Research, LLC received a second request for information from the Federal Trade Commission (FTC) regarding their proposed merger, extending the waiting period under the Hart-Scott-Rodino Act.

LENSAR, Inc. announced a 34% increase in revenue for Q1 2025, driven by higher system sales and procedure volumes, while also reporting a significant net loss due to warrant liability changes related to its pending acquisition by Alcon.

LENSAR announces a 34% revenue increase and a 33% rise in worldwide procedure volumes for Q1 2025, alongside its pending acquisition by Alcon.

Alcon will acquire LENSAR for $14.00 per share in cash, plus a contingent value right of up to $2.75 per share, to enhance its cataract equipment and technology offerings.

LENSAR announces a 38% increase in Q4 revenue and a 27% increase in full-year revenue, driven by strong ALLY system placements and procedure volume growth.

LENSAR's third quarter 2024 results show significant revenue growth and increased system placements, particularly driven by international sales of their ALLY robotic laser system.

LENSAR achieved record placements of its ALLY system and a 19% increase in worldwide procedure volume in the second quarter of 2024, alongside securing key regulatory approvals.

LENSAR, Inc. held its annual meeting of stockholders on May 7, 2024, where two Class I directors were elected and the appointment of PricewaterhouseCoopers LLP as the company's independent auditor was ratified.

LENSAR, Inc. announced a 28% increase in total revenue and a 25% increase in procedure volume for the first quarter of 2024, driven by the adoption of its ALLY Adaptive Cataract Treatment System.

LENSAR, Inc. has granted restricted stock units (RSUs) and performance stock units (PSUs) to three key executives, with PSU vesting tied to revenue targets.

LENSAR, Inc. announced strong financial results for the fourth quarter and full year 2023, driven by increased sales of its ALLY Adaptive Cataract Treatment System.

LENSAR, Inc. has adopted a new incentive award plan and approved salary increases for key executives.

LENSAR, Inc.'s Board of Directors approved 2023 annual cash bonuses for three executives at 103% of their respective target amounts.